IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...

The Company will issue a release after the oral presentation that will include the 5-year OS data, which is the longest OS follow-up in a randomized trial in metastatic uveal melanoma patients. Beyond ...

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

One treatment-related death occurred in the combination therapy group.

Adding the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab to percutaneous hepatic perfusion may improve survival outcomes in patients with ...

Immatics N.V. remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a robust cell therapy pipeline.

IDEAYA Biosciences (NASDAQ:IDYA) executives outlined multiple upcoming clinical catalysts at Citi’s 2026 Virtual Oncology Leadership Summit, led by an end-of-March top-line readout for the company’s ...

Explore the hidden economic burdens of eye cancer in India and the urgent need for awareness, access, and specialized care.

Syncona’s maturing portfolio entering a period of significant clinical and strategic milestones, positioning the business for near-term value creation and enabling returns to shareholdersHigh-calibre ...

Syncona's maturing portfolio entering a period of significant clinical and strategic milestones, positioning the business for near-term value creation and enabling returns to shareholdersHigh-calibre ...

Detailed price information for Bioinvent International Ab (BOVNF) from The Globe and Mail including charting and trades.